Model evaluation of target product profiles of an infant vaccine against respiratory syncytial virus (RSV) in a developed country setting
© 2020 The Author(s) Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in children worldwide and is a significant cause of hospital admissions in young children in England. No RSV vaccine has been licensed but a number are under development. In this work, we prese...
Saved in:
Main Authors: | Timothy Kinyanjui, Wirichada Pan-Ngum, Sompob Saralamba, Sylvia Taylor, Lisa White, D. James Nokes |
---|---|
Other Authors: | GlaxoSmithKline Pharmaceuticals SA/NV |
Format: | Article |
Published: |
2020
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/53561 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
Similar Items
-
Predicting the relative impacts of maternal and neonatal respiratory syncytial virus (RSV) vaccine target product profiles: A consensus modelling approach
by: Wirichada Pan-Ngum, et al.
Published: (2018) -
Modeling household dynamics on Respiratory Syncytial Virus (RSV)
by: Wiriya Mahikul, et al.
Published: (2020) -
Repurposing of antiparasitic niclosamide to inhibit respiratory syncytial virus (RSV) replication
by: Nattamon Niyomdecha, et al.
Published: (2022) -
Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results
by: Oey A.
Published: (2023) -
Mathematical Modeling: Global Stability Analysis of Super Spreading Transmission of Respiratory Syncytial Virus (RSV) Disease
by: Sungchasit R.
Published: (2023)